- Home
- MCRB vs EURK Comparison
MCRB vs EURK Comparison
Compare MCRB & EURK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- EURK
- Stock Information
- Founded
- MCRB 2010
- EURK 2023
- Country
- MCRB United States
- EURK Hong Kong
- Employees
- MCRB N/A
- EURK N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- EURK
- Sector
- MCRB Health Care
- EURK
- Exchange
- MCRB Nasdaq
- EURK NYSE
- Market Cap
- MCRB 72.0M
- EURK 80.0M
- IPO Year
- MCRB 2015
- EURK 2024
- Fundamental
- Price
- MCRB $7.05
- EURK $10.38
- Analyst Decision
- MCRB Hold
- EURK
- Analyst Count
- MCRB 5
- EURK 0
- Target Price
- MCRB $73.67
- EURK N/A
- AVG Volume (30 Days)
- MCRB 93.5K
- EURK 38.0K
- Earning Date
- MCRB 05-07-2025
- EURK 01-01-0001
- Dividend Yield
- MCRB N/A
- EURK N/A
- EPS Growth
- MCRB N/A
- EURK N/A
- EPS
- MCRB 8.98
- EURK N/A
- Revenue
- MCRB N/A
- EURK N/A
- Revenue This Year
- MCRB N/A
- EURK N/A
- Revenue Next Year
- MCRB N/A
- EURK N/A
- P/E Ratio
- MCRB $0.84
- EURK $61.54
- Revenue Growth
- MCRB N/A
- EURK N/A
- 52 Week Low
- MCRB $6.53
- EURK $10.03
- 52 Week High
- MCRB $30.60
- EURK $10.41
- Technical
- Relative Strength Index (RSI)
- MCRB 38.95
- EURK N/A
- Support Level
- MCRB $7.32
- EURK N/A
- Resistance Level
- MCRB $7.86
- EURK N/A
- Average True Range (ATR)
- MCRB 0.63
- EURK 0.00
- MACD
- MCRB 0.10
- EURK 0.00
- Stochastic Oscillator
- MCRB 28.89
- EURK 0.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About EURK EUREKA ACQUISITION CORP
Eureka Acquisition Corp is a newly incorporated blank check company.